GPE
Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma
Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta
Theratechnologies Warns of Temporary Supply Disruption for EGRIFTA SV in Early 2025 Due to Third-Party Facility Shutdown
Theratechnologies, EGRIFTA SV, supply disruption, third-party facility shutdown, HIV drug, 2025
WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.
Johnson & Johnson’s Rybrevant-Lazcluze Combination Shows Superior Survival Trend Over AstraZeneca’s Tagrisso in EGFR-Mutated Lung Cancer
Rybrevant (amivantamab-vmjw), Lazcluze (lazertinib), Tagrisso (osimertinib), EGFR-mutated lung cancer, Non-small cell lung cancer (NSCLC), MARIPOSA study, Survival analysis, Chemotherapy-free treatment
Key Democrat to Oppose Biosecure Act, Citing Concerns Over Legislation’s Design and Impact on U.S.-China Biotech Relations
Biosecure Act, U.S.-China relations, biotech restrictions, national security, WuXi Biologics, BGI, Congressional opposition
Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment
Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies
Psyence Biomed to Acquire Clairvoyant Therapeutics, Expanding Psilocybin-Based Therapeutic Pipeline
Psilocybin, Psyence Biomed, Clairvoyant Therapeutics, Acquisition, Alcohol Use Disorder (AUD), Clinical Trials, Psychedelic Therapeutics
Johnson & Johnson Boosts Talc Settlement by $1.1 Billion Amid Ongoing Negotiations
Johnson & Johnson, Talc Settlement, $1.1 Billion Increase, Cancer Lawsuits, Bankruptcy Plan
Astellas Gene Therapies to Close South San Francisco Manufacturing Facility
Astellas Gene Therapies, South San Francisco, manufacturing facility closure, gene therapy, biotech layoffs
Novartis Expands Radioligand Therapy Production with Two New US Facilities
Novartis, radioligand therapy, RLT, cancer treatment, manufacturing facilities, US expansion